Skip to main content
Erschienen in: Annals of Nuclear Medicine 8/2012

01.10.2012 | Original article

Reduced heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT

verfasst von: Gozde Daglioz Gorur, Esra Alkan Ciftci, Guliz Kozdag, Serkan Isgoren, Murat Alper Oc, Cagla Haksal, Muammer Gur, Hakan Demir

Erschienen in: Annals of Nuclear Medicine | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Objective

A mild decrease in blood pressure and increase in heart rate (HR) are considered normal hemodynamic responses to dipyridamole. In this study, we tried to investigate HR response to dipyridamole and its predictors in patients undergoing gated myocardial perfusion single photon emission computed tomography (SPECT).

Methods

201 consecutive patients undergoing dipyridamole stress Tc99m-MIBI or Tl-201 gated myocardial perfusion SPECT were prospectively enrolled. Dipyridamole was infused over 4 min and radiopharmaceutical was injected 3 min after the end of infusion. A reduced heart rate response to dipyridamole considered if the HR ratio (peak HR/rest HR) was 1.20 or less. Stress (sLVEF), rest (rLVEF) left ventricular ejection fractions, stress and rest motion (SMS, RMS) and thickening scores (STS, RTS) were derived automatically by QGS. Summed stress score (SSS), summed rest score (SRS), and summed difference score (SDS) for myocardial perfusion were calculated. Patients were grouped according to HR response and groups were compared. A logistic regression analysis was used to determine independent predictors of reduced HR response.

Results

Reduced HR response was found in 78 % of patients. Patients with abnormal HR response were more frequently had a history of diabetes mellitus, chronic renal failure, and had lower high-density lipoprotein (HDL) levels. Peak HR, SSS, SRS, sLVEF and rLVEF were lower; rest HR, RTS, and the number of patients with ≤45 % sLVEF and rLVEF were higher in reduced HR response group (all p < 0.05). There was no difference between groups by means of gender, rest and peak systolic or diastolic tension, SDS, SMS, STS, RMS, history of hypertension, peripheral arterial disease, metabolic syndrome, coronary interventions, digoxin, calcium channel blocker or beta blocker usage. Multivariable logistic regression analysis demonstrated that the independent predictors of reduced HR response were HDL, rest HR and SSS. When HDL was removed from the model, chronic renal failure also emerged as an independent predictor.

Conclusion

Reduced HR response to dipyridamole is associated with ventricular dysfunction, cardiac autonomic neuropathy. Low HDL levels also seem to be related with reduced HR response.
Literatur
1.
Zurück zum Zitat Henzlova MJ, Cerqueira MD, Hansen CL, Taillefer R, Yao SS. Stress protocols and tracers ASNC Imaging guidelines for nuclear cardiology procedures. http://www.asnc.org. Henzlova MJ, Cerqueira MD, Hansen CL, Taillefer R, Yao SS. Stress protocols and tracers ASNC Imaging guidelines for nuclear cardiology procedures. http://​www.​asnc.​org.
2.
Zurück zum Zitat Johnston DL, Daley JR, Hodge DO, Hopfenspirger MR, Gibbons RJ. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stres testing: a comparison in 2000 patients. Mayo Clinic Proc. 1995;70:331–6.CrossRef Johnston DL, Daley JR, Hodge DO, Hopfenspirger MR, Gibbons RJ. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stres testing: a comparison in 2000 patients. Mayo Clinic Proc. 1995;70:331–6.CrossRef
3.
Zurück zum Zitat Iskandrian AS, Verani MS, Heo J. Pharmacologic stres testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease. J Nucl Cardiol. 1994;1:94–111.PubMedCrossRef Iskandrian AS, Verani MS, Heo J. Pharmacologic stres testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease. J Nucl Cardiol. 1994;1:94–111.PubMedCrossRef
4.
Zurück zum Zitat Abidov A, Hachamovitch R, Hayes SW, Ng CK, Cohen I, Friedman JD, et al. Prognostic impact of hemodynamic response to adenosine in patients older than 55 years undergoing vasodilator stress myocardial perfusion study. Circulation. 2003;107:2894–9.PubMedCrossRef Abidov A, Hachamovitch R, Hayes SW, Ng CK, Cohen I, Friedman JD, et al. Prognostic impact of hemodynamic response to adenosine in patients older than 55 years undergoing vasodilator stress myocardial perfusion study. Circulation. 2003;107:2894–9.PubMedCrossRef
5.
Zurück zum Zitat Bhateja R, Francis GS, Pothier CE, Lauer MS. Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms. Am J Cardiol. 2005;95:1159–64.CrossRef Bhateja R, Francis GS, Pothier CE, Lauer MS. Heart rate response during dipyridamole stress as a predictor of mortality in patients with normal myocardial perfusion and normal electrocardiograms. Am J Cardiol. 2005;95:1159–64.CrossRef
6.
Zurück zum Zitat Kim YH, Lee KH, Chang HJ, Lee EJ, Chung HW, Choi JY, et al. Depressed heart rate response to vasodilator stress for myocardial SPECT predicts mortality in patients after myocardial infarction. Int J Cardiovasc Imaging. 2006;22:663–70.PubMedCrossRef Kim YH, Lee KH, Chang HJ, Lee EJ, Chung HW, Choi JY, et al. Depressed heart rate response to vasodilator stress for myocardial SPECT predicts mortality in patients after myocardial infarction. Int J Cardiovasc Imaging. 2006;22:663–70.PubMedCrossRef
7.
Zurück zum Zitat Mathur S, Shah AR, Ahlberg AW, Katten DM, Heller GV. Blunted heart rate response as a predictor of cardiac death in patients undergoing vasodilator stress technetium-99m sestamibi gated SPECT myocardial perfusion imaging. J Nucl Cardiol. 2010;17:617–24.PubMedCrossRef Mathur S, Shah AR, Ahlberg AW, Katten DM, Heller GV. Blunted heart rate response as a predictor of cardiac death in patients undergoing vasodilator stress technetium-99m sestamibi gated SPECT myocardial perfusion imaging. J Nucl Cardiol. 2010;17:617–24.PubMedCrossRef
8.
Zurück zum Zitat Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. American Heart Association; National Heart, Lung, and Blood Institute. Circulation. 2005;112:2735–52.PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. American Heart Association; National Heart, Lung, and Blood Institute. Circulation. 2005;112:2735–52.PubMedCrossRef
9.
Zurück zum Zitat De Lorenzo A, Lima RS. Influence of chronic renal failure on the heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT. J Nucl Cardiol. 2008;15:193–200.PubMedCrossRef De Lorenzo A, Lima RS. Influence of chronic renal failure on the heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT. J Nucl Cardiol. 2008;15:193–200.PubMedCrossRef
10.
Zurück zum Zitat Hage FG, Perry G, Heo J, Iskandrian AE. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome. Am J Cardiol. 2010;105:839–43.PubMedCrossRef Hage FG, Perry G, Heo J, Iskandrian AE. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome. Am J Cardiol. 2010;105:839–43.PubMedCrossRef
11.
Zurück zum Zitat Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009;157:771–6.PubMedCrossRef Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, et al. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009;157:771–6.PubMedCrossRef
12.
Zurück zum Zitat Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695–702.PubMedCrossRef Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316:695–702.PubMedCrossRef
13.
Zurück zum Zitat Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA. 1999;281:524–9.PubMedCrossRef Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA. 1999;281:524–9.PubMedCrossRef
14.
Zurück zum Zitat Vashist A, Heller EN, Blum S, Brown EJ, Bhalodkar NC. Association of heart rate response with scan and left ventricular function on adenosine myocardial perfusion imaging. Am J Cardiol. 2002;89:174–7.PubMedCrossRef Vashist A, Heller EN, Blum S, Brown EJ, Bhalodkar NC. Association of heart rate response with scan and left ventricular function on adenosine myocardial perfusion imaging. Am J Cardiol. 2002;89:174–7.PubMedCrossRef
15.
Zurück zum Zitat Venkataraman R, Hage FG, Dorfman TA, Heo J, Aqel RA, de Mattos AM, et al. Relation between heart rate response to adenosine and mortality in patients with end-stage renal disease. Am J Cardiol. 2009;103:1159–64.PubMedCrossRef Venkataraman R, Hage FG, Dorfman TA, Heo J, Aqel RA, de Mattos AM, et al. Relation between heart rate response to adenosine and mortality in patients with end-stage renal disease. Am J Cardiol. 2009;103:1159–64.PubMedCrossRef
16.
Zurück zum Zitat Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707–14.PubMedCrossRef Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707–14.PubMedCrossRef
17.
Zurück zum Zitat Maser RE, Pfiefer MA, Dorman JS, Kuller RH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Arch Intern Med. 1990;150:1218–22.PubMedCrossRef Maser RE, Pfiefer MA, Dorman JS, Kuller RH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Arch Intern Med. 1990;150:1218–22.PubMedCrossRef
18.
Zurück zum Zitat Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med. 2002;19:900–9.PubMedCrossRef Kempler P, Tesfaye S, Chaturvedi N, Stevens LK, Webb DJ, Eaton S, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med. 2002;19:900–9.PubMedCrossRef
19.
Zurück zum Zitat Debono M, Cachia E. The impact of cardiovascular autonomic neuropathy in diabetes: is it associated with left ventricular dysfunction? Auton Neurosci. 2007;132:1–7.PubMedCrossRef Debono M, Cachia E. The impact of cardiovascular autonomic neuropathy in diabetes: is it associated with left ventricular dysfunction? Auton Neurosci. 2007;132:1–7.PubMedCrossRef
20.
Zurück zum Zitat Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008;51:1725–33.PubMedCrossRef Lahiri MK, Kannankeril PJ, Goldberger JJ. Assessment of autonomic function in cardiovascular disease: physiological basis and prognostic implications. J Am Coll Cardiol. 2008;51:1725–33.PubMedCrossRef
21.
Zurück zum Zitat Vita G, Bellinghieri G, Trusso A, Costantino G, Santoro D, Monteleone F, et al. Uremic autonomic neuropathy studied by spectral analysis of heart rate. Kidney Int. 1999;56:232–7.PubMedCrossRef Vita G, Bellinghieri G, Trusso A, Costantino G, Santoro D, Monteleone F, et al. Uremic autonomic neuropathy studied by spectral analysis of heart rate. Kidney Int. 1999;56:232–7.PubMedCrossRef
22.
Zurück zum Zitat Calvo C, Maule S, Mecca F, Quadri R, Martina G, Cavallo-Perin P. The influence of autonomic neuropathy on hypotension during hemodialysis. Clinic Auton Res. 2002;12:84–7.CrossRef Calvo C, Maule S, Mecca F, Quadri R, Martina G, Cavallo-Perin P. The influence of autonomic neuropathy on hypotension during hemodialysis. Clinic Auton Res. 2002;12:84–7.CrossRef
23.
Zurück zum Zitat Kurata C, Uehara A, Ishikawa A. Improvement of cardiac sympathetic innervation by renal transplantation. J Nucl Med. 2004;45:1114–20.PubMed Kurata C, Uehara A, Ishikawa A. Improvement of cardiac sympathetic innervation by renal transplantation. J Nucl Med. 2004;45:1114–20.PubMed
24.
Zurück zum Zitat Marwick TH, Steinmuller DR, Underwood DA, Hobbs RE, Go RT, Swift C, et al. Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure. Transplantation. 1990;49:100–3.PubMedCrossRef Marwick TH, Steinmuller DR, Underwood DA, Hobbs RE, Go RT, Swift C, et al. Ineffectiveness of dipyridamole SPECT thallium imaging as a screening technique for coronary artery disease in patients with end-stage renal failure. Transplantation. 1990;49:100–3.PubMedCrossRef
25.
Zurück zum Zitat Vandenberg BF, Rossen JD, Grover-McKay M, Shammas NW, Burns TL, Rezai K. Evaluation of diabetic patients for renal and pancreas transplantation: noninvasive screening for coronary artery disease using radionuclide methods. Transplantation. 1996;62:1230–5.PubMedCrossRef Vandenberg BF, Rossen JD, Grover-McKay M, Shammas NW, Burns TL, Rezai K. Evaluation of diabetic patients for renal and pancreas transplantation: noninvasive screening for coronary artery disease using radionuclide methods. Transplantation. 1996;62:1230–5.PubMedCrossRef
26.
Zurück zum Zitat De Lorenzo A, Lima RS. Reduced heart rate response to dipyridamole as a marker of left ventricular dysfunction in diabetic patients undergoing myocardial perfusion scintigraphy. Clin Nucl Med. 2009;34:275–8.PubMedCrossRef De Lorenzo A, Lima RS. Reduced heart rate response to dipyridamole as a marker of left ventricular dysfunction in diabetic patients undergoing myocardial perfusion scintigraphy. Clin Nucl Med. 2009;34:275–8.PubMedCrossRef
27.
Zurück zum Zitat de Souza Leão Lima R, Machado L, Azevedo AB, De Lorenzo A. Predictors of abnormal heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT. Ann Nucl Med. 2011;25:7–11.PubMedCrossRef de Souza Leão Lima R, Machado L, Azevedo AB, De Lorenzo A. Predictors of abnormal heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT. Ann Nucl Med. 2011;25:7–11.PubMedCrossRef
Metadaten
Titel
Reduced heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT
verfasst von
Gozde Daglioz Gorur
Esra Alkan Ciftci
Guliz Kozdag
Serkan Isgoren
Murat Alper Oc
Cagla Haksal
Muammer Gur
Hakan Demir
Publikationsdatum
01.10.2012
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 8/2012
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-012-0618-z

Weitere Artikel der Ausgabe 8/2012

Annals of Nuclear Medicine 8/2012 Zur Ausgabe